McCann Health consulting group adds managing directors in NY and London

Consulting word cloud
Thanks to client demand, Consulting at McCann Health has hired two new top executives just five months after opening its doors.

Less than five months after getting off the ground, Consulting at McCann Health is adding two top leaders to manage its rapid growth.

The hiring of managing directors Jamie Avallone in New York and Mark Archer in London is driven by client demand, Simon Holt, president of Consulting at McCann Health, said in an email interview. The practice consolidated McCann Health’s consulting groups in September with the intent to bring fresh thinking to healthcare and pharma strategy. One of its goals is to help pharma companies develop as lifestyle brands versus being simply the product brand owners.

Avallone joins from Manhattan Research, where he headed advisory services, and Archer joins from inVentiv Health, where was executive VP and global head of business development. Archer previously held top roles at Sanofi and pharma services company Quintiles.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“Clients are increasingly inviting us to consult for them as they look for alternatives to their incumbent advisors, particularly when new points of view or fresh energy is required to address often stubborn issues in strategy and operations,” Holt said.

While declining to discuss specific new business, he said the outreach to the new organization has been “terrific” and that the team has worked on several large-scale projects, including handling all commercial functions for organizations and reinventing approaches to issues such as evidence generation and pricing.

As for the future? “One thing for sure, we’ll be steering toward stubborn issues that have driven C-suite executives crazy in pharma and healthcare companies,” he said, while moving away from “the same old same old in professional business advisory services.”


Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.